The study, published July 5 in JAMA Network Open, analyzed 119 FDA 510(k) approval summaries and accompanying marketing materials for devices approved between November 2021 and March 2022. The devices were categorized as adherent, contentious and discrepant. The study found 12.61 percent of devices were discrepant, 6.72 percent were contentious and 80.67 percent were consistent between marketing and FDA clearance summaries.
Here are three other findings:
- Discrepancies between clearance documentation and marketing material was present in 20 percent of devices surveyed.
- Of radiological devices, 82.67 percent were adherent, 4 percent contentious and 13.33 percent discrepant.
- Of cardiovascular devices, 82.61 percent were adherent, 8.7 percent contentious and 8.7 percent discrepant.
Currently, there are no uniform guidelines set by the FDA to regulate artificial intelligence or machine learning-enabled medical devices and “discrepancies between FDA-approved indications for use and device marketing require articulation,” the authors wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.